1-((p-nitrophenyl)carboxymethyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane | 175985-20-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-((p-nitrophenyl)carboxymethyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane
• 英文别名: α-(4-nitrophenyl)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid；2-(4-Nitrophenyl)-2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
• CAS: 175985-20-3
• 化学式: C₂₂H₃₁N₅O₁₀
• 分子量: 525.516
• InChiKey: FRHUKHVHXKFAFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.1
• 重原子数：
  37
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  208
• 氢给体数：
  4
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  1-((p-nitrophenyl)carboxymethyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane 、 gadolinium(III) chloride hexahydrate 、 水 生成
  参考文献：
  名称：

  Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01183
• 作为产物：
  描述：

  在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 1-((p-nitrophenyl)carboxymethyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane
  参考文献：
  名称：

  Chiral Gd-DOTA as a Versatile Platform for Hepatobiliary and Tumor Targeting MRI Contrast Agents

  摘要：

  DOI：

  10.1021/acs.jmedchem.3c01183

文献信息

• Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic
  申请人：The Dow Chemical Company

  公开号：US05756065A1

  公开（公告）日：1998-05-26

  A group conjugates having a functionalized polyaminocarboxylate chelant that form complexes with rare earth-type metal ions, covalently attached to an antibody or antibody fragment, can be used for therapeutic and/or diagnostic purposes.

  一个团体结合了具有功能化聚氨基羧酸螯合剂的抗体或抗体片段，可以与稀土型金属离子形成复合物，可用于治疗和/或诊断目的。
• Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
  申请人：Yang David

  公开号：US20060182687A1

  公开（公告）日：2006-08-17

  Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X 1 -Y-X 2 , wherein Y comprises two or more carbohydrate residues covalently attached to one another, X 1 and X 2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X 1 and X 2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.

  本发明揭示了用于双重成像、双重化疗和放疗的组合物和方法。更具体地说，本发明涉及包含结构X1-Y-X2的化合物，其中Y包含两个或更多碳水化合物残基共价连接在一起，X1和X2是共价连接到Y的诊断或治疗基团，前提是当Y不包含葡萄糖胺残基时，X1和X2是诊断基团。本发明还涉及这些化合物的合成方法，将这些化合物应用于双重成像和治疗增生性疾病的方法，以及用于制备放射性标记治疗或诊断化合物的试剂盒。
• Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0353450A1

  公开（公告）日：1990-02-07

  A group of functionalized polyaminocarboxylate chelants that form complexes with rare earth-type metal ions are disclosed. The complexes can be covalently attached to an antibody or antibody fragment and used for therapeutic and/or diagnostic purposes.

  本发明公开了一组与稀土类金属离子形成络合物的官能化聚氨基羧酸螯合剂。这些络合物可与抗体或抗体片段共价连接，用于治疗和/或诊断目的。
• Diagnostic imaging compositions, their methods of synthesis and use
  申请人：——

  公开号：US20030003048A1

  公开（公告）日：2003-01-02

  Conjugate molecules comprising a ligand bonded to a polymer are disclosed. One such conjugate molecule comprises a ligand bonded to a polymer, a chelating agent bonded to the polymer, and a radioisotope chelated to the chelating agent. The conjugate molecules may be useful in detecting and/or treating tumors or biological receptors. These conjugate molecules may be synthesized without the necessity of preactivation of the ligand using an SCN-polymer-chelating agent precursor. Conjugate molecules incorporating an annexin V ligand are particularly useful for visualizing apoptotic cells. Conjugate molecules incorporating a C225 ligand are particularly useful for targeting tumors expressing EGFR.

  本发明公开了由与聚合物结合的配体组成的共轭分子。其中一种共轭分子包括与聚合物结合的配体、与聚合物结合的螯合剂以及与螯合剂螯合的放射性同位素。共轭分子可用于检测和/或治疗肿瘤或生物受体。这些共轭分子的合成无需使用 SCN 聚合物-螯合剂前体对配体进行预激活。含有附件素 V 配体的共轭分子尤其适用于观察凋亡细胞。含有 C225 配体的共轭分子尤其适用于靶向表达表皮生长因子受体的肿瘤。
• Relaxometric, Structural, and Dynamic NMR Studies of DOTA-like Ln(III) Complexes (Ln = La, Gd, Ho, Yb) Containing a <i>p</i>-Nitrophenyl Substituent
  作者：Silvio Aime、Mauro Botta、Giuseppe Ermondi、Enzo Terreno、Pier Lucio Anelli、Franco Fedeli、Fulvio Uggeri

  DOI：10.1021/ic950981u

  日期：1996.1.1

  We report here the synthesis of the ligand 1-((p-nitrophenyl)carboxymethyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (3) and its La(III), Gd(III), Ho(III), and Yb(III) complexes. The introduction of the p-nitrophenyl substituent on the methylenic carbon of one acetate group does not alter the overall chelating ability of 3 with respect to the parent DOTA ligand. The [Gd(3)](-) complex displays a slightly higher relaxivity than that of [Gd(DOTA)](-), mainly as a consequence of a longer molecular reorientational correlation time (tau(R)), due to the increased molecular dimension of the complex, and of limited changes to the other relaxation parameters. A further increase of relaxivity has been observed upon formation of an inclusion compound with beta-cyclodextrin. The solution structure and dynamics were thoroughly investigated by high-resolution NMR spectroscopy. Of the four possible enantiomeric pairs that could be present in the solutions of monosubstituted derivatives of [Ln(DOTA)](-) complexes, the proton spectra of Ho and Yb derivatives are consistent with the occurrence of only two isomeric species whose structures have been elucidated through analysis of dipolar shifts and 2D-EXSY data. In both species the bulky aromatic group has replaced the acetate proton pointing outward from the coordination cage. Unlike in the DOTA case, in [Ln(3)](-) complexes the isomerization process involves the inversion of the ethylenic groups of the macrocycle rather than the motion of the acetate arms. This behavior is rationalized in terms of steric crowding at the substituent site: minimization of the steric interactions between the aromatic group and the macrocyclic ring protons results in both structural and dynamic selectivity. Interestingly, in the case of the diamagnetic La(III) complex the variable temperature behavior of the C-13 NMR spectra is consistent with an exchange process involving one major species and at least one minor isomer of very low concentration, whose relative population increases with temperature. This causes a persistent exchange broadening of the resonances over a wide range of temperatures.